<DOC>
	<DOC>NCT02626884</DOC>
	<brief_summary>The purpose of this trial is to determine 1. Disease stabilization/response rate after six 21-day cycles of ibrutinib 2. Remission status after six, twelve and 20 21-day cycles of ibrutinib</brief_summary>
	<brief_title>Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Inclusion Criteria (key criteria): 1. Histologically proven relapsed nodular lymphocytepredominant Hodgkin lymphoma (NLPHL) as confirmed by expert review 2. Age at entry 1899 years 3. ECOG status 02 4. Absolute leukocyte count &gt; 2.500/mm3 5. Absolute neutrophil count &gt; 1.000/mm3 independent of growth factor support 6. Platelet count &gt; 100.000/mm3 or &gt; 50.000/mm3 in case of bone marrow involvement independent of transfusion support in either situation 7. GPT and GOT â‰¤ 3 x upper limit of normal (ULN) Exclusion Criteria (key criteria): 1. Classical HL (cHL) or composite lymphoma 2. Known central nervous lymphoma 3. Prior Btk inhibitor treatment 4. Life expectancy &lt; 3 months 5. Major surgery within 4 weeks of study inclusion 6. History of stroke or intracranial hemorrhage within 6 months prior to the first study drug 7. Current anticoagulation with warfarin or equivalent vitamin K antagonists</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>